Biolevate raises €30M Series A to scale life sciences AI

French life sciences AI company Biolevate has raised €30 million in Series A funding co-led by RAISE France and Orange Ventures, with MSD Global Health Innovation Fund, Station F and EQT Ventures participating. Its enterprise agentic AI platform turns scientific and regulatory knowledge into auditable workflows, running up to 100,000 agents concurrently and speeding literature reviews 16-fold. The company is opening a Boston office and plans to double its workforce.

• €30M Series A co-led by RAISE France and Orange Ventures
• Platform runs up to 100,000 AI agents concurrently
• 16x faster literature reviews, 80% efficiency gain in compliance
• Boston office opened; headcount to double again this year